Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

21.67 -0.79 (-3.52%)

Streaming Delayed Price Updated: 12:52 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

53 54 Next >

2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off

March 18, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

March 18, 2025

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Via MarketBeat

Why Hims & Hers Stock Popped on Monday ↗

March 17, 2025

Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?

Via The Motley Fool

2 High-Flying Stocks with Exciting Potential and 1 to Turn Down

March 13, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

Check Out What Whales Are Doing With HIMS ↗

March 12, 2025

Via Benzinga

Should You Buy Hims & Hers Stock on the Dip? ↗

March 11, 2025

Via The Motley Fool

Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

March 13, 2025

From Defiance ETFs

Via GlobeNewswire

Why Hims & Hers Health Stock Just Popped ↗

March 11, 2025

Via The Motley Fool

4 Top Stocks to Buy Under $100 ↗

March 11, 2025

Here are four stocks to buy now that could offer investors upside in the short and long terms.

Via The Motley Fool

Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity? ↗

March 11, 2025

Shutting down an acquisition caught investor attention, but there's more to the story.

Via The Motley Fool

The State of Weight Loss Drugs ↗

March 10, 2025

Via The Motley Fool

Forecasting The Future: 15 Analyst Projections For Hims & Hers Health ↗

March 06, 2025

Via Benzinga

Why Hims & Hers Stock Just Collapsed ↗

March 06, 2025

Via The Motley Fool

Market Whales and Their Recent Bets on HIMS Options ↗

March 06, 2025

Via Benzinga

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

March 10, 2025

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

Via MarketBeat

3 Cold Stocks That Can Bounce Back This Week ↗

March 10, 2025

These three stocks tumbled by at least 20% last week, but they may not be down for long.

Via The Motley Fool

MarketBeat Week in Review – 03/03 - 03/07

March 08, 2025

Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue

Via MarketBeat

Topics Economy

This Could Be a Huge Blow to Hims & Hers Health Stock ↗

March 07, 2025

Via The Motley Fool

Why Hims & Hers Health Stock Sank This Week ↗

February 28, 2025

Via The Motley Fool

Hims & Hers Health Unusual Options Activity For February 28 ↗

February 28, 2025

Via Benzinga

Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It ↗

March 05, 2025

Via The Motley Fool

Why Is Hims & Hers Health Stock Trading Lower On Wednesday? ↗

March 05, 2025

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy.

Via Benzinga

Novo Nordisk Slashes Wegovy Price, Undercutting Hims & Hers Health ↗

March 05, 2025

The news slammed Hims stock. Hims & Hers sells knockoff versions of semaglutide, the chemical backbone behind Wegovy.

Via Investor's Business Daily

Missed the Hims & Hers Rally? Clover Health Could Be Next

March 05, 2025

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

Via MarketBeat

EXCLUSIVE: February's 20 Most-Searched Tickers On Benzinga Pro – Where Do Tesla, Palantir, Alibaba, Nvidia Rank? ↗

March 04, 2025

These were the 20 tickers that Benzinga readers searched for the most during the month of February.

Via Benzinga

Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath ↗

March 04, 2025

U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors.

Via Benzinga

Topics Government World Trade

Short Term Relief Likely ↗

March 02, 2025

Post earnings has seen little bullish follow-through, and this typically means the broad market won’t have much to shout about over the coming weeks.

Via Talk Markets

Topics ETFs Stocks / Equities

Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock? ↗

March 01, 2025

Via The Motley Fool

Sixty Percent Of The Time, It Works Every Time ↗

February 28, 2025

The past few weeks have brought a dramatic change in investor sentiment.

Via Talk Markets

Topics Stocks / Equities

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up ↗

February 28, 2025

Can Hims & Hers Health recover after the FDA removed semaglutide from its drugs shortage list?

Via Investor's Business Daily

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.